But it has not helped any at all though, according to studies done in the US there is little to no evidence that it helps at all, in fact a recent study done in the US show the opposite, it actually was associated with MORE death than the people not given those treatments....the second article has a lot of good information and shows why my point stands that HC was pushed by the Trump team and far right pundits as a "cure", Trump was desperate to be seen as providing a fix or a answer and in typical Trump fashion he hammered the FDA and other groups for not doing enough to ignore the guidelines and rules set in place to prevent using these type pf drugs in ways that could do harm because Trump went off half baked and unproven advice, now they have the data suggesting it isn't helping and could be hurting people and Trump and his team and pundits have all but stopped talking about it completely. Here is the latest from the FDA on it.....they caution against using it.
FDA is concerned that hydroxychloroquine and chloroquine are being used inappropriately to treat non-hospitalized patients for coronavirus disease (COVID-19) or to prevent that disease.
www.fda.gov
Article highlighting the Trump push of this drug and how they have backed away from it since the release of the below study....
After a study showed hydroxychloroquine boosted death rates in COVID-19 patients, the president’s favorite network is suddenly hush-hush on the drug—or attacking the research itself.
www.vanityfair.com
"And the president followed suit. “HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine,”
wrote Donald Trump on March 21, in just one example of the numerous times he promoted the unproven COVID-19 treatment. “Hopefully they will BOTH…be put in use IMMEDIATELY. PEOPLE ARE DYING, MOVE FAST.” And yet, after weeks hawking the drug as a miracle cure, both the network and the president have quietly abandoned it amid new studies showing it has no positive effects on COVID-19 patients and, in fact,
could result in more deaths."
Link to the actual study.....though this still is not the best study as it is retrospective and we still need to wait for the outcome of some ongoing double blind studies being done, this however does highlight the higher number of deaths associated with the use of the drug than seen in other studies.
BACKGROUND Despite limited and conflicting data on the use of hydroxychloroquine in patients with Covid-19, the U.S. Food and Drug Administration has authorized the emergency use of this drug when clinical trials are unavailable or infeasible. Hydroxychloroquine, alone or in combination with...
www.medrxiv.org
METHODS: We performed a retrospective analysis of data from patients hospitalized with confirmed SARS-CoV-2 infection in all United States Veterans Health Administration medical centers until April 11, 2020. Patients were categorized based on their exposure to hydroxychloroquine alone (HC) or with azithromycin (HC+AZ) as treatments in addition to standard supportive management for Covid-19. The two primary outcomes were death and the need for mechanical ventilation.
We determined the association between treatment and the primary outcomes using competing risk hazard regression adjusting for clinical characteristics via propensity scores
RESULTS: A total of 368 patients were evaluated (HC, n=97; HC+AZ, n=113; no HC, n=158).
Rates of death in the HC, HC+AZ, and no HC groups were 27.8%, 22.1%, 11.4%, respectively. Rates of ventilation in the HC, HC+AZ, and no HC groups were 13.3%, 6.9%, 14.1%, respectively. Compared to the no HC group, the risk of death from any cause was higher in the HC group (adjusted hazard ratio, 2.61; 95% CI, 1.10 to 6.17; P=0.03) but not in the HC+AZ group (adjusted hazard ratio, 1.14; 95% CI, 0.56 to 2.32; P=0.72). The risk of ventilation was similar in the HC group (adjusted hazard ratio, 1.43; 95% CI, 0.53 to 3.79; P=0.48) and in the HC+AZ group (adjusted hazard ratio, 0.43; 95% CI, 0.16 to 1.12; P=0.09), compared to the no HC group.
CONCLUSIONS: In this study, we found no evidence that use of hydroxychloroquine, either with or without azithromycin, reduced the risk of mechanical ventilation in patients hospitalized with Covid-19. An association of increased overall mortality was identified in patients treated with hydroxychloroquine alone. These findings highlight the importance of awaiting the results of ongoing prospective, randomized, controlled studies before widespread adoption of these drugs.